YOLT-201

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameYOLT-201
Drug Alias NameYOLT-201
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9
Mechanisms of ActionTransthyretin inhibitors
TargetsTransthyretin
Therapy Area/IndicationsTransthyretin amyloidosisGenetic Diseases, InbornCardiomyopathies +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Yaotang Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesYolTech Therapeutics Co LtdYaotang (Nanjing) Biotechnology Co LtdShanghai Yaotang Biotechnology Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsTransthyretin amyloidosisGenetic Diseases, InbornCardiomyopathies +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A